The global antimalarial drugs market is expected to register lucrative growth over the forecast period 2019-2025. The growth of the market is primarily driven by a substantial increase in malaria-infected persons across the globe. According to the World Health Organization (WHO), an estimated 3.4 billion people in 92 countries are at risk of being infected with malaria and developing a disease, and 1.1 billion are at high risk in 2018. According to the World Malaria Report 2018, there were 219 million cases of malaria globally in 2017 (uncertainty range 203–262 million) and 435,000 mortalities from malaria, representing a decrease in malaria cases and deaths rates of 18% and 28% since 2010, respectively. The burden was heaviest in Africa, where an estimated 93% of all malaria fatalities occurred, and in children aged under 5 years, who accounted for 61% of all mortalities.

A full report of Antimalarial Drugs Market is available at: https://www.omrglobal.com/industry-reports/antimalarial-drugs-market

Moreover, amidst the recent outbreak of COVID-19, the demand for antimalarial drugs such as hydroxychloroquine is increasing at a rapid pace. The drug shows antiviral activity in vitro against coronaviruses, and specifically, SARS-CoV-2. Owing to the drug effectiveness, various virus affected nations have begun using hydroxychloroquine drug on the affected patients. According to the Worldometers, global coronavirus cases reached over 1.4 million with death toll around 83,000 as of 8th April 2020. With nearly 400,500 infected persons, the US is majorly affected due to the virus spread. The US is followed by Spain and Italy with cases around 146,690 and 135,586 respectively as of 8th April 2020.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/antimalarial-drugs-market

The report analyzes the global antimalarial drugs market on the basis of drug class, distribution channel, and geography. Based on drug class, the market is segmented quinine, chloroquine, proguanil, mefloquine, and others. The chloroquine drug class segment is expected to witness the fastest growth in the near terms owing to the wide demand for the drug due to the rapid spread of COVID-19 globally. For instance, on 8th April 2020, the US announced that it has bought over 29 million hydroxychloroquine doses from India. Moreover, Brazil with around 14,000 cases and 688 death tolls has also sought the supply of hydroxychloroquine doses from India. Further, based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and e-commerce.

The global antimalarial drugs market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). RoW region is expected to garner significant revenue over the forecast period due to the rapid surge in the prevalence of malaria in Latin America and the Middle East & Africa. Moreover, Asia-Pacific is expected to register the fastest growth over the forecast period increase in awareness regarding the use of antimalarial drugs for early diagnosis of the infection for better treatment. Further, the market consists of several players that are influencing the global antimalarial drugs industry. Some of the key players of the market include Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd.

Global Antimalarial Drugs Market- Segmentation

Drug Class

• Quinine
• Chloroquine
• Proguanil
• Mefloquine
• Others (Pyrimethamine)

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/antimalarial-drugs-market

Global Antimalarial Drugs Market– Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

Companies Studied

• Alvizia Healthcare Pvt. Ltd.
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• IPCA Laboratories Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Cadila Healthcare Ltd.


About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/


Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404